Document:

Concentra Inc. Board of Directors Compensation Plan

 Exhibit 10.7 
 

 
 Board of Directors Compensation Plan 
 Adopted September 24, 2002; Modified June 26, 2003, July 21, 2005, December 15, 2005, and 
 December 14, 2006 
 Cash Compensation – All Participating Directors*:

 $27,000 annual retainer, payable in equal quarterly installments. 
 $2,000 meeting fee for each regular or special Board of Directors meeting attended. 
 Cash Compensation – Participating Directors Serving
on Standing Committees: 
 $15,000 annual fee to the chairperson of the Audit and Compliance Committee, payable in equal quarterly installments.

 $1,000 committee meeting fee for each regular or special standing Board committee meeting attended as a committee member, not held in conjunction with a
regular or special Board of Directors meeting. 
 $1,000 additional committee meeting fee to the chairperson of each standing Board committee for each
regular or special standing Board committee meeting attended as chairperson, whether or not held in conjunction with a Board meeting. 
 Stock Options
– All Participating Directors: 
 Each Participating Director will receive awards of non-qualified stock options under the Plan as follows:

 Initial. 10,000 shares on the first business day following date of first election to the Board of Directors; and 
 Annual. 4,000 shares on the next business day following each annual meeting of stockholders (other than the annual meeting of stockholders at which
the director is initially elected as a director). 
 Each such Participating Director stock option will have an exercise price no less than 100% of fair
market value on date of award and will expire on the earlier of 10 years from date of award or one (1) year after the holder ceases to serve on the Board of Directors. Initial awards will be immediately vested and exercisable. Annual awards
will vest and be exercisable 25% each year for four years on the anniversary date of award. 
 Other – All Directors: Reimbursement of travel
expenses incurred for meeting attendance. 
  

	*	All Non-Employee Directors (as such term is defined in the Corporation’s 1999 Stock Option and Restricted Stock Purchase Plan), other than Norman C. Payson, M.D.Amendment No. 1

 Exhibit 10.1 
 AMENDMENT NO. 1 
 TO 
 PURCHASE OPTION AGREEMENT 
 AMENDMENT NO. 1, dated December 14, 2006 (the
“Amendment”), to the PURCHASE OPTION AGREEMENT, dated June 9, 2005 (the “Agreement”), by and among EXELIXIS, INC., a Delaware corporation (“Exelixis”), SYMPHONY EVOLUTION
HOLDINGS LLC, a Delaware limited liability company (“Holdings”), and SYMPHONY EVOLUTION, INC., a Delaware corporation (“Symphony Evolution”). Terms used but not defined herein shall have that meaning
ascribed to them in the Agreement. 
 WHEREAS, in consideration for certain amendments of the Amended and Restated Research and Development
Agreement, the Parties desire to amend Section 2 of the Agreement to permit Exelixis to pay up to 100% of Purchase Price in shares of Exelixis Common Stock; and 
 WHEREAS, the parties desire that shares of Exelixis Common Stock representing 33% of the total Purchase Price may be sold immediately following the Purchase Option Closing Date, an additional 33% of the shares may be
sold after 90 days following the Purchase Option Closing Date and the remainder of the shares may be sold after 180 days following the Purchase Option Closing Date. 
 NOW THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows: 
 ARTICLE 1 
 AMENDMENT 
 1.1. Amendment of Section 2(c). Section 2(c), Form of Payment, of the Agreement is
hereby amended and restated in its entirety to read as follows: 
 “(c) Form of Payment. Subject to Sections 2(a)
and 2(e), the Purchase Price may be paid in cash or in a combination of cash and Exelixis Common Stock, at the sole discretion of Exelixis. For the avoidance of doubt, the value of Exelixis Common Stock (determined in accordance with
Section 2(e) hereof) delivered in connection with the exercise of the Purchase Option may constitute up to 100% of the total consideration to be tendered for payment of the Purchase Option Exercise Price, calculated using the Exelixis
Common Stock Valuation (as defined herein) procedure. At the time of the exercise of the Purchase Option, Exelixis may propose to Holdings that Exelixis issue convertible debt securities to Holdings as full or partial consideration for the purchase
price, and Holdings shall, in its sole discretion, be entitled to accept or reject such proposal or agree to other terms of such convertible debt with Exelixis.” 

 1.2. Amendment of Section 2. Section 2 of the Agreement is hereby amended to add a new
sub-section 2(k) to read as follows: 
 “(k) Orderly Distribution. Holdings agrees (and agrees to cause its members and any
subsequent transferees thereof to so agree) that each holder who receives shares of Exelixis Common Stock issued pursuant to Section 2(c) hereof: 
 (i) will be entitled to sell immediately following the Purchase Option Closing Date the number of shares of Exelixis Common Stock representing an aggregate value as of the Purchase Option Closing Date, as determined
in accordance with Section 2(e) of the Agreement, equal to 33% of the total Purchase Price (which may be comprised of cash, convertible debt and Exelixis Common Stock) such holder receives in consideration of its direct or indirect investment
in Symphony Evolution; 
 (ii) will not sell or otherwise transfer, except in a private placement where the transferee agrees
to the restrictions set forth herein, for the period of 90 days after the Purchase Option Closing Date such shares of Exelixis Common Stock in excess of the number of shares representing an aggregate value as of the Purchase Option Closing Date, as
determined in accordance with Section 2(e) of the Agreement, equal to 33% of the total Purchase Price (which may be comprised of cash, convertible debt and Exelixis Common Stock) such holder receives in consideration of its direct or indirect
investment in Symphony Evolution (such shares that are subject to the 90-day transfer restrictions are referred to herein as the “90-Day Lock-up Shares”); 
 (iii) will not sell or otherwise transfer, except in a private placement where the transferee agrees to the restrictions set forth
herein, for the period of 180 days after the Purchase Option Closing Date such shares of Exelixis Common Stock in excess of the number of shares representing an aggregate value as of the Purchase Option Closing Date, as determined in accordance with
Section 2(e) of the Agreement, equal to 66% of the total Purchase Price (which may be comprised of cash, convertible debt and Exelixis Common Stock) such holder receives in consideration of its direct or indirect investment in Symphony
Evolution (such shares that are subject to the 180-day transfer restrictions are referred to herein as the “180-Day Lock-up Shares”); and 
 (iv) will be entitled to sell or otherwise transfer for the period commencing on the day 181 days after the Purchase Option Closing Date and thereafter all shares, without any lock-up restrictions; 
 provided, however, that the foregoing restrictions shall not prevent a holder that is an investment fund from distributing its shares of
Exelixis Common Stock to its partners or members who agree to be similarly bound. The shares of Exelixis Common Stock that are 90-Day Lock-up Shares and 180-Day Lock-up Shares shall be represented by share certificates having legends reflecting the
restrictions of this Section 2(k) applicable to the 90-Day Lock-up Shares and the 180-Day Lock-up Shares, as applicable and provide that such legend expires without 

 further action by the holder thereof or Exelixis on the applicable expiration date therefor. Upon the
request of Holdings, Exelixis shall reasonably consider eliminating all or a part of the foregoing restrictions if favorable market conditions exist for the sale of Exelixis Common Stock subject to the foregoing restrictions.” 
 1.3. Conforming Amendments. Any provisions in the Agreement or any other Operative Document referring to Exelixis’ ability to pay or
otherwise relating to the procedures by which Exelixis may pay part of the Purchase Price in Exelixis Common Stock are hereby amended such that Exelixis may pay all or part of the Purchase Price in Exelixis Common Stock by and in accordance with
this Amendment. If there is any conflict between the Amendment and the Operative Documents, the Amendment shall control. 
 ARTICLE 2

 MISCELLANEOUS 
 2.1. Entire Agreement. This Amendment constitutes the entire agreement between the Parties with respect to the matters covered hereby, and no oral or written statement may be used to interpret or vary the meaning of the terms and
conditions hereof. This Amendment supersedes all prior agreements and understanding with respect to such matters between the Parties. 
 2.2.
Amendment; Successors; Assignment; Counterparts. 
 (a) The Agreement, as amended hereby, shall remain and continue in full force and
effect. 
 (b) The terms of the Agreement, as amended by the Amendment, shall not be altered, modified, amended, waived or supplemented in
any manner whatsoever except by a written instrument signed by each of the Parties. 
 (c) Nothing expressed or implied herein is intended or
shall be construed to confer upon or to give to any Person, other than the Parties, any right, remedy or claim under or by reason of this Amendment or of any term, covenant or condition hereof, and all the terms, covenants, conditions, promises and
agreements contained herein shall be for the sole and exclusive benefit of the Parties and their successors and permitted assigns. 
 (d)
This Amendment may be executed in one or more counterparts, each of which, when executed, shall be deemed an original but all of which taken together shall constitute one and the same Amendment. 
 2.3. Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York. 
 2.4. Severability. If any term or other provision of this Amendment is invalid, illegal or incapable of being enforced by any rule of law or
public policy, all other conditions and provisions of this Amendment shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in a manner materially adverse
to either party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Amendment so as to effect the original intent of the
parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. 
 [SIGNATURES FOLLOW ON NEXT PAGE] 

 IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed as of the day and year
above written. 
  

			
	SYMPHONY EVOLUTION HOLDINGS LLC
		
	By:	 	Symphony Capital Partners, L.P.,
		 	its Manager
		
	By:	 	Symphony Capital GP, L.P.,
		 	its general partner
		
	By:	 	Symphony GP, LLC,
		 	its general partner
		
	By:	 	 /s/ Mark Kessel

	Name:	 	Mark Kessel
	Title:	 	Managing Member
	
	SYMPHONY EVOLUTION, INC.
		
	By:	 	 /s/ Harri Taranto

	Name:	 	Harri V. Taranto
	Title:	 	Chairman of the Board
	
	EXELIXIS, INC.
		
	By:	 	 /s/ Chris Pereira

	Name:	 	Christoph Pereira
	Title:	 	Vice President, Legal Affairs and Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]